NEW YORK (GenomeWeb) – German multiomics tools firm Centogene announced today a collaboration with the medical faculties of the Universities of Greifswald and Rostock to develop diagnostic tools for personalized, immune-based treatments for colon and pancreatic tumors.
As part of the research project, Centogene will genetically profile cancer patients to identify immune-relevant mutations and identify specific biomarkers for early differential diagnosis and therapy monitoring.
The project is supported by the European Union through the European Regional Development Fund, Operational Program Mecklenburg-Vorpommern 2014-2020. Financial and other terms of the deal were not disclosed.
According to Centogene, colon and pancreatic cancer are among the most common tumors, and for pancreatic cancer, the five-year survival rate was just 9 percent in 2017.
Earlier this week, the company announced it will open its first US-based rare disease laboratory in Cambridge, Massachusetts on Aug. 1.